TY - JOUR
T1 - Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer
T2 - Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group
AU - Kooijmans, Esmee C.M.
AU - Mulder, Renée L.
AU - Marks, Stephen D.
AU - Pavasovic, Vesna
AU - Motwani, Shveta S.
AU - Walwyn, Thomas
AU - Larkins, Nicholas G.
AU - Kruseova, Jarmila
AU - Constine, Louis S.
AU - Hamish Wallace, W.
AU - Green, Daniel M.
AU - Bökenkamp, Arend
AU - van der Pal, Helena J.H.
AU - van den Heuvel-Eibrink, Marry M.
AU - Hjorth, Lars
AU - Andrés-Jensen, Liv
AU - Bardi, Edit
AU - van Dalen, Elvira C.
AU - Demoor-Goldschmidt, Charlotte
AU - Becktell, Kerri
AU - Grönroos, Marika
AU - Kieran, Kathleen
AU - Mironova, Denitza
AU - Terenziani, Monica
AU - Veening, Margreet A.
AU - Zieg, Jakub
AU - Onder, Songul
AU - Onder, Ali Mirza
AU - Routh, Jonathan C.
AU - Thompson, Joel
AU - Hudson, Melissa M.
AU - Kremer, Leontien C.M.
AU - Skinner, Roderick
AU - Ehrhardt, Matthew J.
N1 - Publisher Copyright:
© 2025 by American Society of Clinical Oncology.
PY - 2025/7/20
Y1 - 2025/7/20
N2 - PURPOSE Childhood, adolescent, and young adult (CAYA) survivors of cancer are at risk of nephrotoxicity. Surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could slow the progression to higher stages of kidney dysfunction. METHODS The International Late Effects of Childhood Cancer Guideline Harmonization Group established a multidisciplinary panel of 34 experts from 11 countries. The panel performed systematic literature reviews for articles published between 1990 and June 2023, graded the evidence using Grading of Recommendations Assessment, Development, and Evaluation methodology, and formulated recommendations based on evidence, clinical judgment, and consideration of benefits and harms of surveillance. Recommendations were critically appraised by two independent external experts and patient representatives. RESULTS Glomerular dysfunction surveillance is recommended every 2-5 years for survivors treated with ifosfamide, cisplatin, abdominal radiotherapy, total body irradiation, or nephrectomy and is reasonable after carboplatin treatment. We recommend screening for glomerular dysfunction using an estimated glomerular filtration rate (eGFR) equation that includes serum creatinine, preferably combined with serum cystatin C if available. Tubular dysfunction surveillance is recommended once at entry into long-term follow-up and with follow-up as clinically indicated for survivors treated with ifosfamide and is reasonable after cisplatin treatment. CONCLUSION These recommendations inform routine, uniform long-term follow-up care for CAYA survivors of cancer at risk of nephrotoxicity.
AB - PURPOSE Childhood, adolescent, and young adult (CAYA) survivors of cancer are at risk of nephrotoxicity. Surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could slow the progression to higher stages of kidney dysfunction. METHODS The International Late Effects of Childhood Cancer Guideline Harmonization Group established a multidisciplinary panel of 34 experts from 11 countries. The panel performed systematic literature reviews for articles published between 1990 and June 2023, graded the evidence using Grading of Recommendations Assessment, Development, and Evaluation methodology, and formulated recommendations based on evidence, clinical judgment, and consideration of benefits and harms of surveillance. Recommendations were critically appraised by two independent external experts and patient representatives. RESULTS Glomerular dysfunction surveillance is recommended every 2-5 years for survivors treated with ifosfamide, cisplatin, abdominal radiotherapy, total body irradiation, or nephrectomy and is reasonable after carboplatin treatment. We recommend screening for glomerular dysfunction using an estimated glomerular filtration rate (eGFR) equation that includes serum creatinine, preferably combined with serum cystatin C if available. Tubular dysfunction surveillance is recommended once at entry into long-term follow-up and with follow-up as clinically indicated for survivors treated with ifosfamide and is reasonable after cisplatin treatment. CONCLUSION These recommendations inform routine, uniform long-term follow-up care for CAYA survivors of cancer at risk of nephrotoxicity.
UR - https://www.scopus.com/pages/publications/105005760016
UR - https://www.mendeley.com/catalogue/eda5f135-ac8a-3eee-b19b-3e2ee0642548/
U2 - 10.1200/JCO-24-02534
DO - 10.1200/JCO-24-02534
M3 - Article
C2 - 40393013
AN - SCOPUS:105005760016
SN - 0732-183X
VL - 43
SP - 2433
EP - 2448
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 21
ER -